Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
36.04
+0.28 (0.78%)
At close: Jan 14, 2026, 4:00 PM EST
36.00
-0.04 (-0.11%)
Pre-market: Jan 15, 2026, 8:44 AM EST
HRMY Revenue
Harmony Biosciences Holdings had revenue of $239.46M in the quarter ending September 30, 2025, with 28.71% growth. This brings the company's revenue in the last twelve months to $825.94M, up 21.13% year-over-year. In the year 2024, Harmony Biosciences Holdings had annual revenue of $714.73M with 22.80% growth.
Revenue (ttm)
$825.94M
Revenue Growth
+21.13%
P/S Ratio
2.51
Revenue / Employee
$3,081,881
Employees
268
Market Cap
2.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 714.73M | 132.71M | 22.80% |
| Dec 31, 2023 | 582.02M | 144.17M | 32.93% |
| Dec 31, 2022 | 437.86M | 132.42M | 43.35% |
| Dec 31, 2021 | 305.44M | 145.70M | 91.21% |
| Dec 31, 2020 | 159.74M | 153.75M | 2,564.59% |
| Dec 31, 2019 | 6.00M | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
HRMY News
- 1 day ago - Harmony Biosciences Holdings, Inc. (HRMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 3 days ago - Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation - Business Wire
- 8 days ago - Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 weeks ago - Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG - GlobeNewsWire
- 5 weeks ago - Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome - Business Wire
- 6 weeks ago - Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting - Business Wire
- 7 weeks ago - Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation - Business Wire
- 2 months ago - Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence - Business Wire